Swissmedic Authorization After FDA Approval: The Scope and Limits of Art. 13 HMG

A US sponsor may expect an FDA-approved dossier to support a shorter Swiss authorization procedure. Art. 13 HMG requires Swissmedic to take foreign examination results into account where a medicine or procedure is already authorized in a country with comparable medicines control.1Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG) vom 15. Dezember 2000 (SR 812.21), Stand am 1. Januar 2025, Art. 4(1)(a^decies), Art. 9 to 14, Art. 16(2) and Art. 16a HMG (authorization, Swiss applicant, reliance and category-specific protection). That duty is not recognition of the FDA decision. The ordinance and Swissmedic guidance determine the products and documents for which review can be reduced. New active substances face narrow ordinary eligibility conditions, with a separate exceptional power for Swissmedic to act in the public-health interest. The applicant still needs Swiss establishment and the required license. Listing by the federal health office concerns ordinary insurance reimbursement, not every lawful commercial sale; exceptional supply and reimbursement have their own conditions.

1. Why an FDA Approval Is Not a Swiss Marketing Authorization

The US reader's anchor is a single federal decision. An approval under 21 U.S.C. § 355 or a license under 42 U.S.C. § 262 is a federal product-approval decision for US interstate commerce.2Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a) and (j)(5)(F)(ii), § 356(c)(1)(A) and (2)(A)(i), § 360bb(a)(1) and (2), and § 360cc(a) to (c) and (f); Consolidated Appropriations Act, 2026, Pub. L. 119-75, div. J, title VI, § 6605(a) and (b), 140 Stat. 701 (3 February 2026); Public Health Service Act § 351, 42 U.S.C. § 262(a)(1); and 21 C.F.R. § 314.50(a)(5), Content and format of an NDA. Orphan exclusivity runs from approval or licensure for the same drug and approved use or indication, subject to statutory qualifications. The 2026 amendment applies regardless of designation and approval dates; designation alone does not start the seven years. Switzerland is not a member of the European Union, and neither an approval by the FDA nor an authorization granted in the Union is itself a Swiss marketing authorization. Art. 9(1) HMG allows ready-to-use medicinal products to be placed on the Swiss market only once Swissmedic has authorized them, and it reserves international agreements on the recognition of authorizations. The route Swissmedic offers for a product the FDA has approved is not recognition but consideration. Swissmedic's published answers to applicants put the point plainly: Swissmedic does not grant a review under Art. 13 HMG, because the provision says only that the foreign authority's results are taken into account in Swissmedic's own assessment.3Swissmedic, Fragen und Antworten Art. 13 HMG (1 March 2026), questions 9(b), 10–12, 14, 17, 22, 23 and 25: foreign review informs Swissmedic's own assessment; ordinary orphan eligibility, EU-opinion filing and dossier-supply conditions remain. EU decisions are formally made by the Commission: Art. 5(8) of Regulation (EC) No 141/2000 on orphan medicinal products and Art. 10(1) and (2) of Regulation (EC) No 726/2004 establishing the centralized authorization procedure. What that consideration requires is written in Art. 16 to 20 of the Swiss medicines ordinance, the VAM. Under Art. 16(1)(a) VAM, the documents from the foreign procedure supporting an application under Art. 13 HMG, every variation included, may be no more than five years old and must match the state of the foreign authorization. Art. 16(1)(b) to (d) VAM add the foreign authority's assessment decisions with their review results, every item of information Switzerland requires, in particular the product information and the labeling, and a file in a Swiss official language, in English or in a translation whose accuracy the applicant confirms.4Verordnung über die Arzneimittel (Arzneimittelverordnung, VAM) vom 21. September 2018 (SR 812.212.21), Stand am 1. Januar 2026, Art. 7 and Art. 8, Art. 10 to 13, Art. 16 to 20 and Art. 30(5) VAM (reliance conditions, procedures and authorization clocks). Art. 16(4) VAM has Swissmedic publish the list of countries with comparable control. The list valid from 1 June 2026 names Australia, Canada, the member states of the European Economic Area, Japan, New Zealand, Singapore, the United Kingdom and the United States.5Swissmedic, Verzeichnis Liste aller Länder mit vergleichbarer Humanarzneimittelkontrolle (ZL000_00_011, version 3.3, valid from 1 June 2026): the United States is listed, alongside Australia, the EEA member states, Japan, Canada, New Zealand, Singapore and the United Kingdom.

The US sponsor qualifies by country. Whether its dossier qualifies is a narrower question. Swissmedic's guidance on the route, in the version valid from 1 March 2026, requires modules 2.4 to 2.7, 4 and 5 of the Swiss file to be identical to those on which the reference authority granted its approval, and admits deviations in the quality documentation only for batch release, quality control, secondary packaging or packager, pack size and the product name. A finished-product manufacturing site, a primary packaging or a primary packager that differs from the one the FDA approved must be scientifically assessed and is therefore not admissible in an application under Art. 13 HMG, although the Swiss file may list fewer sites than the US one.6Swissmedic, Wegleitung Zulassung Humanarzneimittel nach Art. 13 HMG (ZL000_00_019, version 6.0, valid from 1 March 2026), chapters 5.1–5.9, 6–9, 11, 12.2 and 12.5: dossier identity and age, permitted deviations, ordinary orphan and infection-prevention routes, exceptional public-health review and EU-opinion filing. Reduced review remains a Swissmedic assessment, with its own conditions. The five years run from the foreign approval or from the last approved update of the whole documentation. The guidance also asks for the complete, final and scientifically reasoned assessment report of the reference authority. Where that authority has given the applicant only a report that cannot be read throughout, Swissmedic accepts it but reserves its own assessment of the parts it cannot read, which as a rule adds time and fees. For an FDA reference the guidance lists the approval letter, the questions and the answers to them, the review on the standard or priority track, the summary basis of approval where one exists, an environmental risk assessment and, where one was required, the risk minimization action plan. Swissmedic reads only what the applicant files, since the guidance rules out direct transmission of the foreign assessment by the foreign authority, with one exception for drug master file reports sent by a partner authority of the Access Consortium. Which version of the FDA's review a US sponsor holds, and whether redactions in it will trigger that reservation, is a question answered from the sponsor's own file.

Within the same route, an authorization granted in Europe carries more than an FDA approval does. Art. 16(3) VAM lets Swissmedic approve, for use in Switzerland, the product information of an authorization granted in a member state of the European Union or of the EFTA, and the guidance treats an authorization from the Union's centralized procedure the same way. This does not mean automatic acceptance of the European wording: Swiss-specific requirements remain, and known active substances without innovation follow the Swiss reference product's information. The environmental risk assessment is required only where the reference country is outside the Union.6 For a medicinal product combined with a device, Swissmedic's answers state that an application under Art. 13 HMG cannot refer to an authorization granted outside the Union at all, because Switzerland assesses the device component against the Union's conformity assessment system and approvals such as the FDA's are not valid for that purpose under Swiss law.3 For these aspects of the Swiss filing, an FDA-first sequence can offer less support than a qualifying European reference.

The FDA approval does have one effect in Switzerland before any Swiss filing, and it is an effect the sponsor does not control. Art. 49(1) of the Swiss licensing ordinance, the AMBV, allows a medical professional with a cantonal dispensing license to import small quantities of a ready-to-use medicine not authorized in Switzerland, for a specific patient or for emergencies, where a country with comparable control has authorized it and no alternative is authorized in Switzerland, an authorized alternative is not obtainable on the Swiss market, or switching to one would be inappropriate.7Verordnung über die Bewilligungen im Arzneimittelbereich (Arzneimittel-Bewilligungsverordnung, AMBV) vom 14. November 2018 (SR 812.212.1), Stand am 15. März 2025, Art. 12, Art. 18 and Art. 49 AMBV (holder duties and conditional professional imports without Swiss authorization). Swissmedic's country list applies to that import as it applies to Art. 13 HMG. Art. 71c of the health insurance ordinance, the KVV, then lets compulsory health insurance pay for such an import case by case, where the medicine is authorized for the indication in a country whose authorization system Swissmedic recognizes as equivalent and one of the conditions of Art. 71a(1) KVV is met, among them a high therapeutic benefit against a disease that may be fatal or cause severe and chronic harm with no effective authorized alternative. Reimbursement requires specific insurer approval after consultation of its medical adviser under Art. 71d(1) KVV. The insurer fixes the amount after consulting the authorization holder and may require the provider to import from the country where reimbursement costs least.8Verordnung über die Krankenversicherung (KVV) vom 27. Juni 1995 (SR 832.102), Stand am 1. August 2026, Art. 65, Art. 69, Art. 69a, Art. 70 and Art. 71a to 71d KVV; Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung (Krankenpflege-Leistungsverordnung, KLV) vom 29. September 1995 (SR 832.112.31), Stand am 1. August 2026, Art. 31d, Art. 38e and Art. 38g KLV (listing, early filing and conditional individual reimbursement). A US medicine can therefore reach Swiss patients, at amounts fixed insurer by insurer, each of which may send the provider to the cheapest source country, before its sponsor has decided whether to file in Switzerland at all.

An FDA review may reduce Swissmedic's assessment for a qualifying product and dossier. It does not replace the Swiss applicant or decide reimbursement. Ordinary Swiss authorization, ordinary insurance listing and exceptional supply are distinct legal questions.

2. What the Art. 13 HMG Route Shortens, and for Which Products

The ordinance sorts products before it sorts procedures. Under Art. 17(1) VAM Swissmedic carries out no scientific assessment of its own for a medicine with known active substances that a country with comparable control has already authorized, or for a biosimilar that the European Commission or the FDA has authorized. It does assess, under Art. 17(2) VAM, where two or more comparable authorities have reached contradictory decisions, or where its own earlier assessments, the published literature or information from other authorities give it significant concerns about the foreign decision, and Art. 17(3) VAM confines that assessment to the points of concern.4 For a US biosimilar developer this is where the ordinance puts the FDA level with the European Commission by name. It is also where a divergence between the two becomes a Swiss problem. The guidance treats contradictory decisions as concerns, requires the applicant to disclose every negative decision, withdrawal, suspension or pending review among the comparable authorities, and requires a deviating decision issued while the Swiss application is pending to be reported with its assessment report.6

New active substances are treated differently. Art. 18(1) VAM subjects an application for a medicine with a new active substance, or for a new indication of it, to a comprehensive scientific assessment by Swissmedic, and Art. 18(2) VAM allows Swissmedic to reduce that assessment appropriately in justified cases, on application or of its own motion, on the basis of the foreign results. The guidance reads "justified" narrowly. The ordinary reduced-review routes under Art. 13 HMG cover two categories. One is a medicine with EU or US orphan designation and authorization, with Swiss orphan status granted before filing and indication wording identical to the reference authority's. In the EU, the European Commission makes the designation and centralized authorization decisions following the relevant EMA committee opinions. The second category covers medicines preventing a transmissible infectious disease that can cause serious harm or suffering with a potentially fatal outcome, authorized by the European Commission or the FDA with identical indication wording; it is not confined to vaccines.6 Swissmedic's answers apply the ordinary orphan criteria to oncology products with a new active substance; Swiss orphan status alone does not satisfy them. The EU or US orphan designation and the reference authorization need not come from the same country, but must concern the same medicine (or active substance).3 If the ordinary criteria are not met, Swissmedic gives a preliminary decision refusing their application; absent withdrawal, assessment continues under the ordinary procedure. Separately, the guidance preserves exceptional reduction on Swissmedic's own initiative where required in the public-health interest.

Here the FDA's orphan designation does work that its US function would not suggest. Under 21 U.S.C. § 360bb, orphan designation concerns a rare disease or condition meeting either the fewer-than-200,000-person threshold or the statutory cost-recovery alternative. Under 21 U.S.C. § 360cc, the seven-year protection starts with approval or licensure, not designation, and concerns the same drug for the same approved use or indication, subject to statutory exceptions and the applicable clinical-superiority requirement.2 The Swiss definition in Art. 4(1)(a^decies) HMG covers a medicine for a life-threatening or chronically disabling disease affecting no more than five in ten thousand persons in Switzerland at filing, or a medicine whose status as an important medicine for a rare disease has been recognized by another country with comparable control within the meaning of Art. 13 HMG. A US designation can therefore support Swiss orphan status. Once that status and the required foreign authorization are in place, the product may qualify for reduced review under Art. 13 HMG and, on application under Art. 11b(4) HMG, fifteen years of Swiss document protection. The sequencing is the price of that. Swiss orphan status must be granted before the authorization application is filed, and Swissmedic's time-limits guidance allows the orphan status request up to 210 days of Swissmedic time and 450 days in all.9Swissmedic, Wegleitung Fristen Zulassungsgesuche (ZL000_00_014, version 10.0, valid from 1 September 2025), chapters 5.1.2, 5.2 and 6.2–6.3.4. The published calendar-day schedules distinguish agency and company time; extensions and additional procedural work can change elapsed duration.

What the route saves is less than its heading suggests. The time-limits guidance, in the version valid from 1 September 2025, applies the standard time limits to applications under Art. 13 HMG as a rule, unless they qualify for an accelerated procedure. For a standard new-active-substance application the published schedule is 330 days of Swissmedic time and 540 days including company time. A separate shorter schedule covers known active substances without innovation under Art. 13 HMG, at 195 and 345 days. These are guidance schedules, not guaranteed elapsed ceilings: extensions, deficiencies, additional material and further procedural rounds can affect duration.9 Swissmedic's answers state that the procedure becomes shorter where no list of questions is needed and Swissmedic can issue its preliminary decision directly,3 and the guidance applies the 60 percent reduction of the flat fees that Swissmedic's fee ordinance provides where Swissmedic can rest on the reference authority's results.6 For a qualifying orphan medicine with a new active substance, reliance on the foreign results can reduce the fee and avoid a round of questions. Art. 13 HMG does not by itself shorten the standard published schedule.

A second limit follows the form of the US approval. Under 21 U.S.C. § 356(c), the FDA may grant accelerated approval for a serious or life-threatening disease or condition on a qualifying surrogate or earlier clinical endpoint reasonably likely to predict clinical benefit, and may require studies to verify and describe that benefit.2 Art. 19(1) VAM provides that where a comparable country has authorized a medicine only conditionally, for lack of data on quality, safety and efficacy and with special obligations, its results are taken into account only for a temporary authorization under Art. 9a HMG. The Swiss texts do not say by name whether an FDA accelerated approval is such a conditional authorization. Swissmedic's answers do say that an EU centralized authorization under exceptional circumstances cannot serve as the reference at all, because Switzerland has no comparable procedure.3 The temporary authorization has its own gate. Art. 9a(1) HMG requires a disease that is life-threatening or disabling, compatibility with the protection of health, a high expected therapeutic benefit and the absence in Switzerland of an authorized, alternatively usable and equivalent medicine. Swissmedic initially grants it for at most two years, with extensions possible during assessment of timely conversion material or in scientifically justified exceptional cases,10Swissmedic, Wegleitung Befristete Zulassung Humanarzneimittel (ZL109_00_001, version 18.0, valid from 1 June 2025), chapters 1.1.1, 6.4 and 6.5.2–6.5.3: initially at most two years with obligations and no document protection; conversion and narrowly conditioned extensions are distinct procedures. and no document protection attaches to it until it is converted into an ordinary authorization.11Swissmedic, Wegleitung Unterlagenschutz (ZL000_00_024, version 8.0, valid from 1 February 2026), chapters 5.1.1, 5.2, 5.2.4 and 5.2.5; Wegleitung Übertragung der Zulassung (ZL404_00_001, version 2.1, valid from 1 July 2025), chapters 5.1.1–5.1.2. Protection depends on the product and authorization category; temporary authorization carries none. A later transfer requires approval and the outgoing holder's signed assignment.

Routes Planned Before FDA Approval

The fast-track procedure and international work-sharing routes can be planned before FDA approval, although Orbis also has a route for applications filed after the FDA decision. Each requires its own eligibility and submission planning. Art. 7 VAM allows an accelerated authorization procedure for a promising prevention or therapy of a serious, disabling or life-threatening disease where authorized treatments are absent or unsatisfactory and a high therapeutic benefit is expected.4 Swissmedic's guidance asks for the request three to twelve months before the application and measures the benefit against the therapies authorized and available in Switzerland on the date of the request, not against the US standard of care.12Swissmedic, Wegleitung Beschleunigtes Zulassungsverfahren (ZL104_00_002, version 12.0, valid from 1 April 2025), chapters 2 and 5.1–5.3: cumulative eligibility, a Swiss therapeutic comparator and a preliminary request three to twelve months before the authorization application. The guidance schedule for the accelerated procedure is 140 days of Swissmedic time and 350 days including company time, subject to the procedural qualifications described above.9 For an oncology product accepted by the FDA into Project Orbis, Swiss filing within 30 days after the FDA submission is Type A, with concurrent review and shorter time limits. An application made after the FDA has decided is Type C: the FDA shares its unredacted assessment reports, and Swissmedic reviews on the standard time limits and issues a list of questions.13Swissmedic, Wegleitung Project Orbis (ZL000_00_048, version 4.0, valid from 1 June 2026), chapters 2, 5.1.3 and 5.2.1–5.2.3: FDA admission to the program, distinct Type A/B/C timing, and separate national decisions and labeling.

The Access Consortium, in which Swissmedic works with the Australian, Canadian, Singaporean and UK authorities, can share assessment of a new active substance submitted to at least two members, simultaneously or as agreed with them. Eligibility and a common evaluation plan are settled beforehand; each authority retains its own decision, and the United States is not a member.14Access Consortium, New Active Substance Work-sharing Initiative (NASWSI): Operational Procedures (version 1.2, effective 1 June 2025), pp. 3–8: joint review by at least two members, planned simultaneous or agreed filing, and independent national decisions. Swissmedic, Wegleitung Fristen Zulassungsgesuche (ZL000_00_014, version 10.0, valid from 1 September 2025), chapter 6.3.4. Art. 20 VAM lets an application already under standard review turn to the route under Art. 13 HMG on request when an EMA recommendation or a positive authorization from a comparable authority arrives during the Swiss procedure. The guidance applies that switch only where Swissmedic's own assessment has raised no significant concerns and the switch is expected to produce a faster decision, with the ordinary conditions for a new active substance and the separate exceptional public-health power preserved.6 The routes impose different planning requirements: the fast-track request three to twelve months before the application, Orbis Type A within 30 days after the US submission, and Access coordinated with at least one other member. Access normally asks for an expression of interest at least three months before filing, or six months for its Promise priority pilot.

3. Who Can Hold a Swiss Authorization for a US Medicine

The FDA's new-drug application rules contemplate a signatory abroad: under 21 C.F.R. § 314.50(a)(5), where the person signing the NDA does not reside or have a place of business in the United States, the NDA must identify and be countersigned by an attorney, agent or other authorized official who does.2 Swiss law has no agent model for the holder. Art. 10(1)(c) HMG requires the applicant itself to have a domicile, registered office or branch in Switzerland, and Art. 10(1)(b) HMG requires it to hold a manufacturing, import or wholesale license from the competent authority.1 A holder that releases ready-to-use medicines onto the Swiss market must meet the further conditions of Art. 12(1) AMBV, among them a person with pharmacovigilance expertise for the reporting duties, who need not belong to the company but whose responsibilities Art. 12(2) AMBV requires to be set out in writing in every case. The person with technical responsibility for such a licensee must, under Art. 18(2) AMBV, hold a pharmacist's diploma and the necessary manufacturing experience, or other training Swissmedic recognizes on proof of sufficient knowledge and experience. Through market release, that person must ensure that each batch meets the applicable requirements and that the whole supply chain complies with the authorization and good distribution practice.7 A US company therefore reaches the Swiss market through a Swiss subsidiary or branch that holds the license and the staff these provisions require, or through a Swiss company that holds the authorization on its behalf.

The second option moves more than paperwork. The holder is Swissmedic's counterparty for the life of the authorization, and an application under Art. 13 HMG requires it to file the reference dossier under the identity requirements described above, together with the FDA's reviews and the correspondence behind them. Swissmedic's answers add that everything in the reference dossier, confidential material included, must be supplied by the authorization holder, with the restricted part of a drug master file the only exception.3 Using a distributor as holder therefore requires an arrangement for the confidential reference material needed for the Swiss filing; the restricted drug-master-file exception remains. The authorization is transferable under Art. 10 VAM,4 and document protection stays with the product through a transfer of the authorization, its revocation or its renunciation, but a transfer is itself a Swissmedic procedure: the incoming holder applies, as a rule at least three months before the transfer date, and the application must carry a declaration of assignment signed by the outgoing holder.11 A partner whose distribution agreement is ending holds that signature. The reference authority is sticky as well. The guidance requires the reference authority, once chosen, to be kept for later variation applications made on the route under Art. 13 HMG,6 so a Swiss authorization built on the FDA's review keeps the FDA's assessment as the reference for variations on that route, whatever the Union later decides.

Authorization starts continuing obligations even before commercial launch. Under Art. 16(2) HMG an ordinary first authorization normally lasts five years; temporary authorization or health protection can require a shorter term. Art. 12 VAM normally requires a renewal application at least six months before expiry, although Swissmedic may specify a different filing date in its authorization decision. Art. 11(1) VAM requires the holder to notify Swissmedic within 30 days after the end of the first year if the product has not been placed on the market in that year. Under Art. 16a(1)(a) HMG and Art. 13(4) VAM, failure to market the product within three years ordinarily leads to revocation. The period starts at authorization unless patent protection then prevents marketing, in which case it starts at patent expiry. Art. 13(3) VAM exempts products authorized solely for an emergency or intended exclusively for export.4 Waiting for a pricing decision is not itself an exception to these sunset rules.

4. Reimbursement Requires a Separate Listing Procedure

Ordinary reimbursement by Swiss compulsory health insurance depends on listing, through a procedure run separately from Swissmedic authorization. Exceptional individual reimbursement has its own conditions. Under Art. 52(1)(b) of the health insurance act, the KVG, the BAG draws up the Spezialitätenliste with its prices, and Art. 32(1) KVG requires every reimbursed service to be effective, appropriate and economical.15Bundesgesetz über die Krankenversicherung (KVG) vom 18. März 1994 (SR 832.10), Stand am 1. Juli 2026, Art. 32(1) and Art. 52(1)(b) KVG; Bundesgesetz über die Krankenversicherung (KVG) (Massnahmen zur Kostendämpfung, Paket 2), Änderung vom 21. März 2025, BBl 2025 1108, AS 2026 294, Art. 52d KVG and commencement decision of 5 June 2026; Verordnung über die Krankenversicherung (KVV), Änderung vom …, Vernehmlassungsvorlage vom 18. Februar 2026, Art. 69c(3) KVV (provisional reimbursement enacted but not yet operative; international-joint-review treatment proposed). Eidgenössisches Departement des Innern and Bundesamt für Gesundheit, Änderung der Verordnung vom 27. Juni 1995 über die Krankenversicherung (KVV) und der Krankenpflege-Leistungsverordnung vom 29. September 1995 (KLV) (Umsetzung des Kostendämpfungspakets 2 im Arzneimittelbereich): Erläuternder Bericht zur Eröffnung des Vernehmlassungsverfahrens (18 February 2026), pp 7 and 28–29 (timing and proposed international-joint-review treatment). Art. 65(1) KVV admits a medicine to the list only with a valid Swissmedic authorization, and Art. 65(4) KVV requires the holder of an original product to state its patents and supplementary protection certificates, with their expiry dates, in the listing application. Art. 69(4) KVV ordinarily permits filing once Swissmedic's preliminary decision has confirmed the indication and dosage; the EDI, the federal home affairs department, may require authorization first for particular applications. Art. 69a KVV also permits qualifying early applications before that preliminary decision, following consultations involving Swissmedic and subject to the conditions in Art. 31d KLV. Early filing does not itself confer reimbursement.8 The mechanics of the price itself, the comparison with prices abroad and the therapeutic cross-comparison, are examined in the analysis of Swiss pharmaceutical pricing, and the way a Swiss price feeds the US most-favored-nation benchmark in the analysis of Swiss pricing and US most-favored-nation pressure.

A faster Swissmedic assessment can advance the ordinary listing milestone, but it is not the only route to an earlier BAG filing. Qualifying cases can use the early-filing procedure. An authorized product outside the list may receive individual reimbursement under Art. 71b KVV only where a condition in Art. 71a(1) KVV is met and the insurer grants specific approval after consulting its medical adviser. The insurer determines reimbursement after consulting the holder, using the foreign-price comparison and prescribed discounts rather than an unconstrained negotiation.8 Withholding an SL application therefore does not guarantee either reimbursed transactions or freedom from a public list price. Art. 70 KVV permits the BAG to list a Swissmedic-authorized product or indication of major importance to medical supply without an application or against the holder's request, and to set its price. Where qualifying individual cases arise, they can produce insurer-specific reimbursement amounts. Lawful marketing does not itself require SL listing, but private-pay supply and conditional insurance reimbursement are different commercial propositions.

Swiss document protection follows authorization, independently of listing. Under Art. 11a HMG the documents of a medicine with at least one new active substance, authorized in the procedure of Art. 11 HMG, are protected for ten years, and Art. 12 HMG governs reliance by an essentially similar product on those protected test results. Without the holder's consent, authorization through that reliance route cannot issue before the day after protection expires, and the application may be filed at the earliest two years before expiry.1 The US comparison is the five-year bar on submitting certain abbreviated applications under 21 U.S.C. § 355(j)(5)(F)(ii), measured from approval of the qualifying new-active-moiety drug, with a specified patent-challenge filing permitted after four years.2 Swissmedic's guidance states that it is immaterial whether the product is already authorized abroad or has received protection there, that the protection is ordered and published with the authorization under Art. 30(5) VAM and applies independently of any patent, and that a temporary authorization carries none until it is converted.11 The Swiss term therefore runs from the Swiss authorization date, not from the FDA's, and how that clock compares with the Union's for a biosimilar entrant is set out in the analysis of biosimilar entry and EU exclusivity. A later Swiss filing does not shorten the Swiss document protection, which starts only when Swissmedic authorizes. The patent estate, which runs on dates of its own, is another matter.

Parliament has already legislated a bridge between the two legs, and it had not opened by the date of publication. The amendment to the KVG of 21 March 2025 inserts an Art. 52d KVG, under which a medicine with a demonstrated high medical need that Swissmedic has given the status for treatment in one of the accelerated procedures may, on the application of the designated holder and after consultation of the competent commission, be admitted to a provisional list and reimbursed from the Swissmedic authorization date. The BAG would set a provisional price subject to a possible refund and decide any application for definitive listing within 24 months after provisional admission.15 On 5 June 2026 the Federal Council brought four of the amendment's provisions into force on 1 July 2026 and left the rest, Art. 52d KVG among them, to a later date, and Art. 52d KVG was not in force in the consolidated law applicable on 22 September 2026. The February consultation texts set out proposed implementing rules. The amendment of the KVV that the Federal Council put out for consultation on 18 February 2026 would give the same status to medicines that Swissmedic reviews in an international joint assessment, which its explanatory report says includes procedures such as Access and Orbis, and the report expected the changes to enter into force at the start of 2027.15 The draft does not mention the route under Art. 13 HMG, which Swissmedic's time-limits guidance files under the standard procedures unless the application qualifies for an accelerated one.9 On the draft as it stood, the status would come from one of Swissmedic's accelerated procedures, the fast-track procedure in particular, or from an Orbis or Access review, and not from the reference to the FDA as such. These proposed provisions did not provide an operative reimbursement entitlement on the article's date.

5. Swiss Launch Decisions for US Sponsors

The first questions are about timing, and the routes answer them in opposite directions. Art. 13 HMG normally relies on a foreign authorization; for an EU centralized reference, Swissmedic accepts a positive CHMP or HMPC opinion at initial filing, with the Commission decision supplied when available. Project Orbis Type A presupposes a Swiss filing within 30 days of the US submission, and the Access Consortium a filing coordinated with at least one other member country. The fast-track procedure presupposes a request three to twelve months before the Swiss application, measured against Swiss therapies on the date of the request. For the ordinary orphan route, Swiss orphan status must be granted before filing; the orphan-status request has a guidance schedule totaling 450 days including company time. The separate infection-prevention route and exceptional public-health power require their own assessment. A US filing date set before a Swiss date has therefore already narrowed the choice among these routes. Whether the five-year limit on the age of the foreign dossier will still be met when the Swiss pricing environment looks acceptable, and whether the FDA approval is the right reference at all, when an authorization in the Union that follows later would carry the product information, a device component or a differently worded indication, are questions whose answers change with each month of the global sequence.

The second set concerns the holder. Whether a Swiss subsidiary can be licensed, and its technically responsible person and pharmacovigilance person appointed, by the date of the Swiss filing is a corporate question with a regulatory deadline, since Art. 10(1) HMG sets the establishment and license conditions for the applicant and not only for the eventual holder. Where a distributor holds the authorization instead, whether the distribution agreement returns the complete regulatory file and the authorization itself on the sponsor's timetable, and at what price, is a question the Swiss statute leaves to the contract. And whether the FDA's review, as the sponsor holds it, will satisfy Swissmedic without the reserved assessment of illegible parts is a question the sponsor can answer only from its own correspondence with the FDA, since on the route under Art. 13 HMG Swissmedic takes no assessment report directly from the FDA.

The third set concerns distinct legal clocks. Authorization normally starts the marketing-sunset period, but a patent blocking marketing at that point delays its start and statutory exceptions remain. Document protection depends on the product and authorization category. A preliminary decision usually permits the listing application; qualifying early filing can precede it. Staying outside the list does not guarantee reimbursement or prevent the BAG from listing a product on its own initiative. Where individual reimbursement is available, the insurer determines the amount under the applicable statutory conditions after consulting the holder. The launch plan therefore needs separate assumptions for authorization, supply and payment, rather than a single Swiss approval date.

Neither the Federal Council's bill of 3 September 2025 nor its consultation draft of 19 June 2026 proposes to amend Art. 13 HMG. The consultation on the latter runs until 16 October 2026. Among other changes, the draft would extend the simplified procedure of Art. 14(1)(a^bis) HMG, limited by the statute in force to active substances authorized for at least ten years in a member state of the European Union or EFTA, to active substances authorized for that period in any country with comparable medicines control, with comparable indication, dosage and administration route. The explanatory report says the wider country group includes the United States. It would also write Swissmedic's duty to publish the list of those countries into the statute as a new Art. 9b(4) HMG.16Entwurf, Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG), Änderung vom …, BBl 2025 3018, Bundesrat, Botschaft zur Änderung des Heilmittelgesetzes vom 3. September 2025, BBl 2025 3017; Bundesrat, Änderung des Heilmittelgesetzes 3b, Vernehmlassungsvorlage: Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG), Änderung vom … (19 June 2026), Art. 9b(4) HMG and Art. 14(1)(a^bis) HMG and Art. 14(1)(a^ter) HMG (proposals; neither named text amends Art. 13 HMG). Eidgenössisches Departement des Innern and Bundesamt für Gesundheit, Änderung des Heilmittelgesetzes: Erläuternder Bericht zur Eröffnung des Vernehmlassungsverfahrens (19 June 2026), p 41; EDI, Änderung des Heilmittelgesetzes: Eröffnung des Vernehmlassungsverfahrens (19 June 2026), p 1 (consultation closing date). It is a proposal in consultation, not law, and it concerns medicines with long-established active substances rather than new US approvals. Whether a later revision will move further toward reliance on FDA decisions for new active substances is not a question the consultation addresses.

The choice of Swiss holder determines who can supply the regulatory file and cooperate in a later transfer. The choice of reference authority affects the material Swissmedic can use. Those decisions interact with product eligibility, reimbursement and protection periods, even where the commercial launch date remains undecided.